• 1
    Dutch Association of Comprehensive Cancer Centres. Guidelines for oncological and palliative care in the Netherlands. 2004. []. Accessed 7 January 2008.
  • 2
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:1536.
  • 3
    DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaiaPJ, CreasmanWT, editors. Clinical Gynecologic Oncology, 6th edn. St Louis, MO: Mosby, Inc., 2002. pp. 289343.
  • 4
    Harries M, Gore M. Part I: Chemotherapy for epithelial ovarian cancer—treatment at first diagnosis. Lancet Oncol 2002;3:52936.
  • 5
    Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. Eur J Cancer 1998;34:221825.
  • 6
    Petterson F. Annual Report on the Results of Treatment in Gynecological Cancer, FIGO, Vol. 22. Stockholm: International Federation of Gynecology and Obstetrics, 1994.
  • 7
    FIGO. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:2634.
  • 8
    Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:15966.
  • 9
    Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:19.
  • 10
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:124859.
  • 11
    Hoskins WJ, McGuire WP, Brady MF, Homesley WT, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:9749.
  • 12
    Omura GA, Brady MF, Homesly HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:113850.
  • 13
    Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993;71:60614.
  • 14
    Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:5327.
  • 15
    Zhang L, Cornejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:20313.
  • 16
    Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:33529.
  • 17
    Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:7916.
  • 18
    Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an RO resection for gastric carcinoma. J Clin Oncol 2003;21:364750.
  • 19
    Clark TG, Sterwart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001;85:94452.
  • 20
    Chi DS, Palayekar MJ, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol 2008;108:1914.
  • 21
    de Jong D, Eijkemans MJ, Lie Fong S, Gerestein CG, Kooi GS, Baalbergen A, et al. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology 2008;72:293301.
  • 22
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:20516.
  • 23
    Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:10319.
  • 24
    Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol 1998;70:212.
  • 25
    van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999;18:68194.
  • 26
    Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:36187.
  • 27
    Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med 1990;9:130325.
  • 28
    Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York: Wiley & Sons, Inc., 2000.
  • 29
    Warwick J, Kehoe S, Earl H, Luesley D, Redman C, Chan KK. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 1995;72:151317.
  • 30
    Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:17580.
  • 31
    van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989;7:76973.
  • 32
    Zeimet AG, Marth C, Müller-Holzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994;170:54954.
  • 33
    Chalas E, Welshinger M, Engellener W, Chumas J, Barbieri R, Mann WJ. The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 1992;166:9747.
  • 34
    Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 2004;92:21114.
  • 35
    Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, et al. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:88893.
  • 36
    Schneider D, Halperin R, Halperin D, Bukovsky I, Hadas E. Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system. Eur J Gynaecol Oncol 1998;19:54752.
  • 37
    Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 1996;41:1402.
  • 38
    Teramukai S, Ochiai K, Tada H, Fukushima M; Japan Multinational Trial Organization OC01-01. PIEPOC: a new prognostic index for advanced epithelial ovarian cancer. J Clin Oncol 2007;25:33026.
  • 39
    Clark TG, Stewart M, Rye T, Smyth JF, Gourley C. Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort. J Clin Oncol 2007;25:566970.